Fact-checked by Grok 2 weeks ago

Isomaltooligosaccharide

Isomaltooligosaccharides (IMOs) are short-chain carbohydrates consisting of 2 to 10 glucose monomers primarily linked by α-(1→6)-glycosidic bonds, with some α-(1→4) linkages, rendering them partially resistant to digestion in the human upper gastrointestinal tract. They occur naturally in trace amounts in fermented foods like miso and honey, but are predominantly produced commercially through enzymatic hydrolysis of starch sources such as corn or tapioca using enzymes like α-amylase, pullulanase, and α-glucosidase. As dietary fibers, IMOs function as prebiotics by selectively stimulating the growth of beneficial gut microbiota, including Bifidobacterium and Lactobacillus species, while inhibiting pathogens and increasing short-chain fatty acid production in the colon. Physicochemically, IMOs exhibit high solubility, moderate viscosity, and thermal and pH stability (optimal at pH 4–6), with a sweetness level of approximately 60% that of and a caloric value about half that of digestible carbohydrates. Their resistance to by human enzymes contributes to their low , making them suitable for managing blood sugar levels. Production follows good manufacturing practices, yielding syrup or powder forms that have GRAS status by the U.S. (FDA; up to 30 g/day intake) and are approved as a ingredient by the (EFSA) and , with EFSA extending approved uses to additional foods and supplements in 2024. In food applications, IMOs serve as low-calorie sweeteners, bulking agents, and modifiers in products like baked goods, , beverages, and infant formulas, enhancing without promoting dental caries due to non-fermentability by oral . Health-wise, they support gastrointestinal function by alleviating , modulating immune responses, and improving mineral absorption; clinical studies also indicate benefits in reducing , triglycerides, and associated with metabolic disorders like , , and . Ongoing research explores their role in synbiotics for enhanced efficacy against conditions such as .

Chemical Composition

Molecular Structure

Isomaltooligosaccharides (IMOs) are a of short-chain carbohydrates consisting primarily of α-D-glucose oligomers linked by α-(1→6) glycosidic bonds, with degrees of polymerization () typically ranging from 2 to 10. These oligosaccharides are derived from and feature a general structure where glucose residues form chains or branches through these specific linkages, setting them apart from other glucose polymers. Key components of IMOs include (DP 2), panose (DP 3), and higher homologs such as (DP 3), isomaltotetraose (DP 4), and isomaltopentaose (DP 5). For example, is a composed of two D-glucose units connected via an α-(1→6) , with the molecular \ce{C12H22O11}. Panose, a trisaccharide, exhibits a branched configuration with one α-(1→6) linkage and one α-(1→4) linkage, represented by the \ce{C18H32O16}. The branched structure of IMOs arises from the α-(1→6) glycosidic bonds, which connect glucose units at the C6 hydroxyl group, enabling side chains and distinguishing them from the linear α-(1→4)-linked chains found in maltodextrins. In commercial IMO mixtures, these α-(1→6) linkages predominate at 40–95%, while minor α-(1→4) or α-(1→3) linkages occur naturally, comprising the balance and contributing to structural variability.

Physical and Functional Properties

Isomaltooligosaccharides (IMOs) typically appear as a to off-white powder, facilitating easy handling and incorporation into various formulations. They exhibit high in , with dissolution rates approaching 99% or greater, allowing for concentrations up to several grams per 100 mL without precipitation at . Solutions of IMOs demonstrate low viscosity, comparable to or lower than at equivalent concentrations, which supports their use in beverages and syrups without significantly altering . Functionally, IMOs provide a relative sweetness of 40-60% that of , offering a mild suitable for reducing overall content in products while maintaining . They possess good thermal , retaining integrity during heating processes common in manufacturing, and demonstrate robustness across a wide range (2-10), with over 99% under acidic conditions. This is partly attributable to their predominant α-(1→6) glycosidic linkages. IMOs contribute approximately 2.4 kcal/g, reflecting their partial fermentability in the gut rather than complete digestion. Their glycemic index is low, measured at 34.66 ± 7.65, which supports applications in managing blood glucose responses. Additionally, IMOs are non-cariogenic, as they do not promote dental plaque formation and may inhibit biofilm development by oral bacteria.

Production Methods

Natural Occurrence

Isomaltooligosaccharides (IMOs) occur naturally in small amounts in various fermented foods and , primarily as a result of microbial activity during processes. These oligosaccharides are formed through the partial of by α-glucosidase enzymes produced by microorganisms such as and yeasts involved in . For instance, in traditional Asian fermented products like , , and , IMOs arise from the enzymatic action of and other microbes on starch substrates. Similarly, in Western fermented foods such as and , microbial α-glucosidase contributes to their incidental production during lactic . Typical concentrations of IMOs in these natural sources are low, generally less than 1-2% of the total composition, making them insufficient for commercial extraction and highlighting their role as minor components rather than primary constituents. In honey, isomaltose—a key disaccharide in IMOs—comprises 0.5-1.5% of the free sugars. Miso contains approximately 1.1% IMOs, while sake averages about 5 mg/mL (0.5%). Soy sauce and other fermented soy products also harbor trace amounts, though exact quantification varies by production method. These levels reflect the incidental nature of IMO formation in traditional processing. IMOs were first recognized as a minor component in Japanese in the late 1970s to early 1980s through analyses of free sugars in fermented pastes, marking an early scientific identification of their natural presence in traditional s. This discovery underscored their long of consumption, dating back centuries in Asian diets via staples like (dating to the 7th century) and . However, their low natural yields necessitated later industrial development for broader applications.

Industrial Synthesis

Isomaltooligosaccharides (IMOs) are primarily produced industrially through enzymatic transglucosidation of sourced from corn, , or , involving the rearrangement of α-(1→4) linkages to α-(1→6) linkages. The process begins with the of slurry (typically 25-30% w/v) using thermostable α-amylase from at temperatures above 100°C and pH around 6.0, yielding dextrins with a (DE) of about 25. This is followed by using fungal α-amylase from species at 55-60°C, producing maltose-rich substrates, and then transglucosidation with transglycosylating α-glucosidase (tAG), often from , at 50-60°C and pH 5.0-5.8 for 24-48 hours to form IMOs with degrees of (DP) ranging from 2 to 9. Purification of the crude IMO syrup involves multiple steps to achieve high purity, including to remove insoluble residues, decolorization with , concentration by , and ion-exchange chromatography to eliminate salts and impurities. Residual glucose and are often removed via yeast fermentation using , resulting in final products with 40-50% IMO content initially, which can reach up to 90% purity after processing. In optimized enzyme cocktail approaches, pullulanase from naganoensis is incorporated alongside α-amylase, β-amylase from barley bran, and α-transglucosidase, enabling simultaneous and transglucosidation at 55°C for 13 hours, yielding approximately 49% IMOs (primarily , isomaltotriose, and panose). Alternative production methods include acid-enzymatic , where is partially hydrolyzed with dilute acid (e.g., HCl) before enzymatic transglucosidation to enhance substrate availability, though this is less common due to potential of linkages. Microbial represents another approach, utilizing strains such as that secrete transglucosidase enzymes directly into the medium during , producing long-chain IMOs (DP up to 12) with yields around 40-60% under controlled conditions at 37°C and ~5.5–7. Since the 2010s, developments have focused on engineering and process integration, such as simultaneous and transglycosylation () using thermostable tAG from Thermoanaerobacter species, which boosts productivity by 20-30% and achieves >90% α-(1→6) linkage purity in products with DP 2-9. These advancements, including recombinant cocktails, have reduced reaction times from days to hours while minimizing by-product formation, enhancing scalability for commercial syrups.

Physiological Effects

Digestion and Absorption

Isomaltooligosaccharides (IMOs) exhibit resistance to by salivary and pancreatic α-amylase primarily due to their predominant α-(1→6) glycosidic linkages, which differ from the α-(1→4) bonds targeted by these enzymes. This structural feature results in minimal absorption in the , with less than 10% of ingested IMOs being digested and absorbed as glucose, depending on the (DP) and composition. Short-chain components (DP 2–3) may undergo partial by brush-border enzymes like sucrase-isomaltase, but higher-DP fractions remain largely intact. Due to this low digestibility, IMOs are often classified as indigestible dextrins or soluble dietary fibers in regulatory contexts, exerting osmotic effects in the gut by drawing and promoting bowel movement. Pharmacokinetically, undigested IMOs rapidly to the colon, typically within 4–6 hours post-ingestion, where they become available for microbial processing. In the colon, 50–90% of IMOs are fermented by the , with beneficial genera such as and serving as primary metabolizers. This bacterial breakdown yields (SCFAs), including , propionate, and butyrate, which are absorbed by the colonic and contribute to . The process supports IMO's prebiotic classification by selectively stimulating these microbes.

Prebiotic and Health Benefits

Isomaltooligosaccharides (IMOs) are recognized as prebiotics, defined as non-digestible food ingredients that beneficially affect the by selectively stimulating the growth and/or activity of one or a limited number of bacterial in the colon, thereby improving . As such, IMOs resist digestion in the upper and reach the colon intact, where they serve as substrates for fermentation by beneficial . IMOs selectively promote the proliferation of beneficial gut bacteria, including and species, while increasing the production of (SCFAs) such as , propionate, and butyrate. This modulation of the gut microbiota has been linked to improved bowel regularity and reduced , with clinical studies from the 2000s to the 2020s demonstrating benefits; for instance, supplementation at 10 g/day for 30 days enhanced defecation frequency in constipated elderly individuals. Additionally, IMOs exhibit low cariogenicity, as they are not fermented by cariogenic oral bacteria like , supporting dental health by minimizing acid production and enamel demineralization. Metabolically, IMOs contribute to lowering blood levels, with a 4-week human trial using 30 g/day showing reductions in total . A 2024 review underscores the potential of IMOs in managing , , (IBD), and through microbiota-mediated improvements in insulin sensitivity, lipid profiles, and gut barrier function. Furthermore, IMOs support immune health by modulating responses and reducing proinflammatory cytokines such as TNF-α and IL-1β, thereby alleviating inflammation in conditions like . Evidence for these benefits primarily stems from and , with human trials indicating modest effects, such as increased SCFA levels following consumption. In the , health claims related to IMOs, including those on glycemic responses, have been deemed insufficiently substantiated by the since the 2010s, leading to their rejection.

Safety and Side Effects

Tolerability

Isomaltooligosaccharides (IMOs) are generally well-tolerated in healthy individuals at moderate doses, with no significant gastrointestinal symptoms reported in clinical trials up to approximately 50 g of carbohydrates from IMOs. A randomized, double-blind, crossover published in (n=26 and n=10 healthy adults) found no differences in symptoms such as , , , , or loose stools after single doses of IMOs providing 50 g carbohydrates compared to , as assessed by visual analog scales. Breath levels, an indicator of colonic , also remained unchanged, suggesting minimal acute discomfort at these levels. At higher doses exceeding 30 g per day, common side effects may include , , and loose stools, attributed to rapid colonic of undigested IMOs. IMOs are well-tolerated up to 30 g/day (~0.5 g/kg for a 60 kg ) chronically, with mild effects possible above this; the acute threshold is approximately 1.5 g/kg body weight, similar to other non-digestible carbohydrates. In the aforementioned 2018 trial, while the tested dose elicited no issues, extrapolations from higher-dose contexts indicate increased short-chain production from , potentially contributing to discomfort. Individuals with (IBS) may experience exacerbated symptoms, including heightened gas and abdominal discomfort, due to IMOs' fermentable nature, though specific trials in this population are limited. No allergenicity has been reported, with regulatory assessments confirming IMOs pose no allergenic risk beyond standard labeling for source materials. Long-term intake shows no evidence of , as supported by chronic rodent studies administering up to 5% IMOs in the diet with no adverse effects on growth, organ function, or ; adaptive changes may further improve tolerance over time with regular consumption. As of 2024, the (EFSA) confirmed the safety of extended uses of IMOs in various foods and supplements up to 30 g/day for the general population over 10 years of age, with no additional concerns identified. The recommended daily intake of isomaltooligosaccharides (IMOs) for achieving prebiotic effects in healthy adults is typically 5-10 grams, based on studies demonstrating benefits for modulation at these levels. Regulatory assessments, including FDA GRAS notices, indicate that up to 30 grams per day is safe for general consumption, with exposures in typical food uses not exceeding this threshold in multiple servings. To minimize gastrointestinal side effects, the upper limit for chronic intake is generally set at 30 grams per day, as per regulatory assessments, though tolerance thresholds can reach 1.5 grams per kilogram of body weight for acute consumption without inducing diarrhea (approximately 90-105 grams for a 60-70 kg individual). In functional foods targeting bowel health, contextual dosing of 4-8 grams per serving is common, aligning with clinical trial protocols for efficacy without discomfort. For children, intake should be adjusted proportionally by body weight, starting at lower levels to account for smaller size and developing gut sensitivity, though specific pediatric guidelines remain limited and follow general fiber scaling. Individuals new to IMOs are advised to begin with 2-5 grams daily to assess personal , gradually increasing as needed. There are no established Recommended Dietary Allowances (RDAs) specifically for IMOs, but intake recommendations align with broader goals of 25-30 grams total per day for adults to support overall digestive . Post-2018 guidelines from bodies like the EFSA and prebiotic associations emphasize individualized dosing based on gut sensitivity, with maximum supplement levels capped at 30 grams per day for the general population to ensure tolerability.

Applications

In Food Products

Isomaltooligosaccharides (IMOs) serve as low-calorie sweeteners and bulking agents in everyday food products, with primary applications in beverages like sports drinks, items such as and cookies, and snacks including nutrition bars. These uses leverage IMOs' relative sweetness of approximately 60% that of , allowing partial replacement of sugars while maintaining product volume and structure. In formulations, IMOs fulfill functional roles by improving and retention in low-sugar , masking bitterness in functional beverages, and providing binding properties in snacks; they are commonly incorporated at levels of 5-20% by weight. For instance, in cakes and desserts, addition levels up to 20 g/100 g enhance crumb softness without compromising bake quality. Representative examples include their use in yogurts, breakfast cereals, and products like chocolates to boost soluble content while preserving sensory attributes. Market trends indicate increasing adoption of IMOs in low-carb and keto-friendly products since the early 2020s, driven by demand for sugar-reduced options that deliver improved and no lingering aftertaste. The global IMO market, valued at USD 87.2 million in 2025, is projected to grow at a 7.9% CAGR through 2032, reflecting this shift toward functional ingredients in snacks and baked goods. IMOs demonstrate strong processing compatibility, maintaining stability during high-shear operations like and thermal treatments in up to 180°C, which supports their integration into diverse manufacturing lines without degradation.

In Nutraceuticals

Isomaltooligosaccharides (IMOs) are incorporated into prebiotic supplements, aids, and gut health formulas, often in forms such as powders and capsules with typical servings of 5-15 g to support modulation and digestive wellness. In products, IMOs contribute to reduced body weight and fat mass by influencing composition and metabolic responses, as demonstrated in studies on and adults. For gut health, these formulations promote beneficial and immune function, particularly in perinatal or high-stress contexts like athletic training. These benefits align with broader prebiotic effects on conditions like and , as detailed in physiological sections. In medical applications, IMOs serve as an adjunct in due to their low , which results in slower postprandial glucose and insulin responses compared to simple sugars. Emerging 2024 research highlights their potential in (IBD) therapy through modulation, reducing histological scores and alleviating symptoms by enhancing beneficial and lowering . IMOs are formulated as synbiotics when combined with , enhancing probiotic viability and synergistic effects on gut barrier integrity and metabolic health. They are also included in solutions for relief, increasing bowel movement frequency and fecal water content in clinical trials. Product dosages typically range from 2-10 g per serving, with recommendations tailored for vulnerable groups such as the elderly to improve diversity and reduce dependence, or athletes to optimize via enhanced . Innovations include forms of IMOs for pharmaceutical delivery, facilitating easy integration into therapeutic liquids for sustained prebiotic effects. Post-2020 research has explored blends incorporating IMOs, showing reduced and improved profiles in metabolic models.

Regulatory Status

Approvals and Restrictions

In the United States, isomaltooligosaccharide (IMO) received Generally Recognized as Safe (GRAS) status from the Food and Drug Administration (FDA) in 2009 through GRAS Notice No. 246, submitted by BioNeutra, allowing its use as an alternative sweetener in various foods at levels up to 15 grams per serving. However, in 2018, the FDA denied inclusion of IMO in its list of approved dietary fibers under the updated nutrition labeling rules, citing its partial digestibility (approximately 30-50% fermented in the gut, with the remainder absorbed as glucose), which does not meet the criteria for non-digestible carbohydrates with established physiological benefits. As a result, labeling IMO as "dietary fiber" is prohibited unless at least 75% of the carbohydrate is indigestible, and manufacturers must declare it as a carbohydrate contributing to total sugars or other appropriate categories on nutrition facts panels, with ongoing post-market surveillance required for novel applications. In the , was authorized as a in 2017 under Implementing () 2017/2470, which established the Union list of authorized s pursuant to the Novel Foods () 2015/2283, permitting its use in foods and supplements with specifications limiting mono- and disaccharides to no more than 25% of the product. The (EFSA) has not approved any claims for , deeming evidence insufficient to substantiate benefits such as reduced post-prandial glycaemic responses, based on evaluations under Article 13 of () No 1924/2006. Recent updates in 2025 extended its permitted uses to additional categories like and table-top sweeteners, but without altering core specifications or granting claims. In other regions, IMO has long been approved for use. included IMO on its Foods for Specified Health Uses (FOSHU) list in the , enabling -related labeling for products promoting intestinal , with over 50% of FOSHU items incorporating it by 2002. In , IMO is permitted as a under the National Food Safety Standard GB 2760-2024, allowing its use in appropriate amounts across various food categories without specified maximum levels for most applications. approved IMO (as VitaFiber) as a ingredient in 2017, with issuing a letter of no objection for its use in foods at levels providing up to 30 grams per day. As of 2025, no major global regulatory changes have occurred, though ongoing petitions in Asian markets, particularly and , seek expanded claims related to prebiotic effects.

Commercial Products

Isomaltooligosaccharides (IMOs) are primarily produced by a few key manufacturers, with holding a dominant position in global supply through companies such as Baolingbao Biology Co., Ltd. and Shandong Bailong Group Co., Ltd. In , producers like Food Company and Nikon Shikuhin Kako Co., Ltd. contribute significantly to high-quality IMO output, while in , BioNeutra North America Inc. specializes in branded products such as VitaFiber IMO. Commercial IMOs are available in several forms to suit industrial and consumer applications, including powders with purities typically exceeding 90-95% and syrups containing 70-75% solids. Branded variants like VitaFiber are offered as soluble fibers in both powder and syrup formats, emphasizing prebiotic properties and low-calorie sweetening. These products are supplied as bulk ingredients to food and manufacturers worldwide. The global IMO market, valued at approximately USD 75.3 million in 2024, is projected to grow at a (CAGR) of 7.8% through 2034, driven by increasing demand for prebiotic fibers in functional foods and supplements. s are incorporated into a wide array of products, including protein bars, shakes, items, and dietary supplements available in health stores. Consumer-facing options, such as prebiotic gummies and fiber-enriched beverages, are increasingly accessible in retail channels across , , and . Recent trends in the IMO sector include a shift toward high-purity formulations (>90% α-(1→6)-linked oligosaccharides) since 2020, facilitated by advancements in enzymatic production that have boosted yield efficiency by up to 40%. This has supported growing exports from Asian producers to the and EU markets, enhancing availability for clean-label product development.

References

  1. [1]
    Isomaltooligosaccharide - an overview | ScienceDirect Topics
    Isomaltooligosaccharides are formed when monomers of glucose are linked by (1,6)-glycosidic linkages and are obtained enzymatically from corn starch with alpha ...Missing: definition | Show results with:definition
  2. [2]
    Current Research on the Role of Isomaltooligosaccharides in ...
    For example, IMOs exhibit prebiotic properties that stimulate the growth of beneficial bacteria. In addition, they can modulate immune responses, enhance ...
  3. [3]
    Prebiotic Type Spotlight: Isomaltooligosaccharides (IMOs)
    The IMO structure determines their physicochemical and biological properties such as viscosity, solubility, sweetness, as well as influences their prebiotic ...Missing: definition | Show results with:definition
  4. [4]
    [PDF] Application A1123 Isomalto-oligosaccharide as a Novel Food
    Dec 13, 2016 · (a) chemical structure—IMO is a mixture of glucose oligomers with α 1→6 glycosidic linkages that include isomaltose, panose, isomaltotriose, ...
  5. [5]
    [PDF] GRAS Notice 674, Isomalto-oligosaccharides - FDA
    Oct 11, 2016 · Structural formulas of some of the identified mono-, di-, and oligo-saccharides (DP 3 to 5) are presented below in Figure II.A-1. Table II.A-1 ...
  6. [6]
    White Isomaltooligosaccharide Powder IMO900 Food Grade For ...
    White Isomaltooligosaccharide Powder IMO900 Food Grade For Milk Powder ; High Light: water soluble dietary fiber. ,. resistant dextrin ; Brand Name, elite-indus.
  7. [7]
    Process for the preparation of isomaltooligosaccharide-hydrogenated
    IMO is preferably a white powder or clear syrup for application in foods. When IMO in powder form is heated the powder has a tendency to change to a slight ...
  8. [8]
    Corn Organic Isomalto Oligosaccharide Powder-Supplier - Sgnutri
    Jun 10, 2025 · Formulation-Friendly: High Solubility, Neutral Color, Excellent Stability. In powder form, IMO dissolves quickly in water (≥99% solubility) ...
  9. [9]
    Isomalto-oligosaccharides: Recent insights in production technology ...
    ... isomaltooligosaccharide and BIOLIGOTMIL7010 isomaltooligosaccharide was ... stability and storage stability in a broader temperature and pH range. View.
  10. [10]
    Isomaltose - an overview | ScienceDirect Topics
    In addition, isomaltose has a sweetness equivalent to 30–60% of sucrose, and is low in calories, so it can be used as a sweetener instead of sucrose, and can be ...
  11. [11]
    Products/Isomaltooligosaccharide Powder - Plant Extract / Alfa ...
    Isomaltooligosaccharide Powder ; Stable and Versatile: Resistant to high temperatures and acidic conditions, making it suitable for a variety of food and ...
  12. [12]
    [PDF] December 8 - 2008 BioNeutra Inc.
    Jan 27, 1997 · Under high acidic conditions like pH 2.0 and high alkaline condition like pH 10, VitaSugar-IMO molecules was found to be > 99% stable.
  13. [13]
    Isomalto-oligosaccharides: Recent insights in production technology ...
    IMOs typically consist of glucose units linked by α-1,2, α-1,3, α-1,4 and α-1,6 glucosidic bonds (Fig. 1). These range degrees of polymerization (DP) 2 i.e. ...Missing: glycosidic | Show results with:glycosidic
  14. [14]
    Isomalto-oligosaccharide (VitaFiber) - Canada.ca
    May 4, 2017 · Isomalto-oligosaccharide is a food ingredient added to foods with a relative sweetness level equal to approximately 60% of sucrose.Missing: properties | Show results with:properties
  15. [15]
    Improvement of IMO production and prebiotic properties using ...
    IMO are also popular due to their beneficial properties including mild taste, low glycemic index (34.66 ± 7.65) (Ojha et al., 2015), low calorie sweetener ...
  16. [16]
    Purification and characterization of cold-adapted and salt-tolerant ...
    Nov 11, 2022 · Isomaltooligosaccharides are one kind of non-digestible ... In order for the inhibition rate of dental plaque biofilms to be 90%, the ...
  17. [17]
    Starch biotransformation into isomaltooligosaccharides using ...
    Jun 21, 2018 · The present study first identified the biotransformation of starch as a novel preparation method was investigated using the alpha-transglucosidase-producing ...
  18. [18]
    An improved process of isomaltooligosaccharide production in ...
    This study sought to improve IMO synthesis during lactate fermentation in kimchi by inoculating the kimchi fermentation mix with a starter and sugars.Missing: sourdough | Show results with:sourdough
  19. [19]
    The successful synthesis of industrial isomaltooligosaccharides lies ...
    IMO is a mixture of short-chain carbohydrates with linkages α-(1→4) and α-(1→6). The typical components present in IMO are: Glucose: α-D-Glc; Maltose: α-D-Glc-( ...
  20. [20]
    Highly efficient enzymatic preparation of isomalto-oligosaccharides ...
    Most commercial IMOs are enzymatically produced from starch through transglycosylation [2], [3]. The typical commercially scaled starch-as-substrate process ...
  21. [21]
    [PDF] OPTIMIZATION OF ENZYMATIC SYNTHESIS OF ISOMALTO ...
    Isomalto-oligosaccharides are composed by one maltose unit and up to eight glucose units linked by α-1,6-glycosidic bonds with a chemical structure.<|control11|><|separator|>
  22. [22]
    Production of a Series of Long-Chain Isomaltooligosaccharides from ...
    Apr 3, 2023 · The presence of only the α-(1,6)-glycosidic bonds in IMOs makes them resistant to cleavage by α-amylase, which only cleaves α-(1,4)-glycosidic ...
  23. [23]
    None
    Summary of each segment:
  24. [24]
  25. [25]
  26. [26]
    Prebiotic Isomaltooligosaccharide Provides an Advantageous ...
    In vivo studies showed the effective role of IMOSs to increase bifidobacteria and lactobacilli in the gut of humans and rodents [19,20,21], and to decrease ...
  27. [27]
    Isomalto-oligosaccharides related health claims - EFSA
    Oct 19, 2010 · Scientific Opinion on the substantiation of health claims related to isomalto-oligosaccharides and reduction of post-prandial glycaemic responses.Missing: rejected | Show results with:rejected
  28. [28]
    Gastrointestinal Tolerance and Glycemic Response of ... - MDPI
    Mar 3, 2018 · Polyols provide sweet taste while yielding a low glycemic index, are non-cariogenic, and thus can be used as sugar replacers [6]. However, ...
  29. [29]
    Gastrointestinal Tolerance and Glycemic Response of ... - NIH
    Mar 3, 2018 · The physicochemical properties of isomaltooligosaccharides make them highly functional as sweeteners, due to their higher stability in food and ...
  30. [30]
  31. [31]
    Isomalto-oligosaccharides ameliorate visceral hyperalgesia with ...
    Apr 24, 2017 · This study aimed to investigate the therapeutic effects of the prebiotic isomalto-oligosaccharides (IMO) on visceral hypersensitivity (VHS) in rats and to ...Missing: benefits | Show results with:benefits
  32. [32]
    Extension of use of isomalto‐oligosaccharide as a novel food ...
    Feb 5, 2024 · No gastrointestinal adverse effects were reported by the participants (Subhan et al., 2020). The Panel notes that no adverse events related to ...Missing: side | Show results with:side
  33. [33]
  34. [34]
    Extension of use of isomalto‐oligosaccharide as a novel food ...
    The NF is a mixture of glucose oligomers linked through α- (1–4) or α- (1–6) glucosidic bonds, including mono- and disaccharides (about 30%), as well as ...
  35. [35]
    Extension of use of isomalto‐oligosaccharide as a novel food ... - NIH
    Feb 5, 2024 · Isomalto-oligosaccharide (IMO) is a novel food of glucose oligomers (DP 3-9) with mono/disaccharides, proposed for use in foods and supplements.Missing: isomaltooligosaccharide | Show results with:isomaltooligosaccharide
  36. [36]
    A Survey of Commercially Available Isomaltooligosaccharide-Based ...
    Isomaltooligosaccharides (IMOs) are in protein/fiber bars, shakes, and supplements, marketed as high fiber, prebiotic fiber, or low-calorie sweetener. They are ...Missing: uses | Show results with:uses
  37. [37]
    Effect of fructo-oligosaccharide and isomalto ... - ScienceDirect.com
    Dec 15, 2016 · The addition of FO or IMO to frozen dough improved the baking quality even after frozen storage for up to 8 weeks.
  38. [38]
    Isomalto-oligosaccharide Market Share & Forecast, 2025-2032
    Isomalto-oligosaccharide is a highly effective prebiotic that selectively feeds beneficial bacteria in the gut. It can help maintain a balanced intestinal ...
  39. [39]
    Effect of non-digestible oligosaccharides on body weight in ...
    Dec 15, 2023 · Effect of different levels of xylooligosaccharide in sugar on glycemic index and blood glucose response in healthy adults. Journal of ...
  40. [40]
    Effects of Dietary Isomaltooligosaccharide Levels on the Gut ...
    Isomaltooligosaccharides (IMO), as a functional oligosaccharide, is considered to act as a prebiotic, since it can modulate the composition and metabolic ...
  41. [41]
  42. [42]
    Use of isomalto-oligosaccharide in the treatment of lipid profiles and ...
    IMO induced a significant increase in number of bowel movements and hence improvement of constipation in 76.3% + 30.9% of patients during the 4-week treatment.Missing: oral rehydration
  43. [43]
    [PDF] Prebiotic properties of isomaltooligosaccharides from cassava as a ...
    Mar 21, 2023 · The most dominant property of IMO is its prebiotic lineament, leading to better gut health, absorption of minerals, cholesterol control, and ...
  44. [44]
    Assessing the therapeutic potential of long-chain ...
    Jul 16, 2024 · ... absorption within the small intestine. Hence, IMOs may undergo ... isomaltooligosaccharide. Biomolecules. 2023;13:300. Article CAS ...
  45. [45]
    The Declaration of Certain Isolated or Synthetic Non-Digestible ...
    Jun 20, 2018 · This guidance is intended to identify for manufacturers specific, additional isolated or synthetic non-digestible carbohydrates that we intend to propose ...Missing: denied | Show results with:denied
  46. [46]
    Questions and Answers on Dietary Fiber - FDA
    Jul 25, 2024 · A manufacturer cannot include isolated or synthetic non-digestible carbohydrates that are the subject of pending petitions in the declaration of ...
  47. [47]
    Foods for Specified Health Uses (FOSHU)
    FOSHU refers to foods containing ingredient with functions for health and officially approved to claim its physiological effects on the human body.Missing: Isomaltooligosaccharide 1990s
  48. [48]
  49. [49]
    Isomalto-oligosaccharide Market Size, Growth Analysis 2025-2034
    The global isomalto-oligosaccharide market size was valued at USD 75.3 million in 2024 and is estimated to grow at 7.8% CAGR from 2025 to 2034. As individuals ...Missing: carb keto
  50. [50]
    Isomalto-oligosaccharide Market | Global Market Analysis Report
    Countries Covered, USA, Germany, France, UK, Japan, South Korea, Mexico, and 40+ countries ; Key Companies Profiled, Baolingbao Biology, Shandong Fuyang, Tate & ...
  51. [51]
    USA | BioNeutra North America Inc.
    VitaFiber® IMO is a high-quality, high-purity isomaltooligosaccharide (IMO) made by enzymatic conversion of starch. Because of its mild pleasant flavour ...
  52. [52]
  53. [53]
    [PDF] A Survey of Commercially Available Isomaltooligosaccharide-Based ...
    Oligosaccharides are small polysaccharides ranging in degree of polymerization (DP) from 3 to 9 or “oligosaccharides DP >. 2” (Jones 2014), or as “carbohydrates ...
  54. [54]
    Organic Isomaltooligosaccharide Prebiotic: Natural Gut Health Support
    Rating 5.0 (177) Technological advancements in enzymatic hydrolysis have improved yield efficiency by 40% since 2020, enabling higher-purity (>90%) IMO production at reduced ...